Skip to main content

A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.

Publication ,  Conference
Coleman, RL; Enserro, D; Spirtos, N; Herzog, TJ; Sabbatini, P; Armstrong, DK; Kim, B; Fujiwara, K; Walker, JL; Flynn, PJ; Secord, AA; Cohn, DE ...
Published in: Journal of Clinical Oncology
May 20, 2018

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

5501 / 5501

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Coleman, R. L., Enserro, D., Spirtos, N., Herzog, T. J., Sabbatini, P., Armstrong, D. K., … Mannel, R. S. (2018). A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study. In Journal of Clinical Oncology (Vol. 36, pp. 5501–5501). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.5501
Coleman, Robert L., Danielle Enserro, Nick Spirtos, Thomas J. Herzog, Paul Sabbatini, Deborah Kay Armstrong, Byoung Kim, et al. “A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.” In Journal of Clinical Oncology, 36:5501–5501. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5501.
Coleman, Robert L., et al. “A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 5501–5501. Crossref, doi:10.1200/jco.2018.36.15_suppl.5501.
Coleman RL, Enserro D, Spirtos N, Herzog TJ, Sabbatini P, Armstrong DK, Kim B, Fujiwara K, Walker JL, Flynn PJ, Secord AA, Cohn DE, Brady MF, Mannel RS. A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5501–5501.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

5501 / 5501

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences